Stay up to date on Aegle updates and publications.
Company Updates
03/25/2024: Aegle’s Phase 1/2a clinical trial of AGLE-102TM in individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB) is now open for enrollment
01/08/2024: Aegle Therapeutics Corp. Announces Positive Data for the First Patient in a Phase 1/2a Clinical Trial Dosed With AGLE-102™, a Novel Extracellular Vesicle Therapy
08/16/2023: Aegle Therapeutics Corp. Announces First Patient Dosed in Phase 1/2a Clinical Trial Administering a Novel Extracellular Vesicle Therapy
10/10/2022: Aegle Therapeutics presents at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.
10/05/2022: Aegle Therapeutics presents at the 4th Annual Extracellular Vesicle-based Therapeutic Development Summit in Boston, MA.
12/02/2020: Aegle Therapeutics’ big mission: Tackling a horrific pediatric disorder
10/08/2020: Aegle Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of AGLE-102
10/06/2020: Aegle Therapeutics Receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for AGLE-102 for Patients with Dystrophic Epidermolysis Bullosa
10/01/2020: FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa
09/29/2020: Aegle Therapeutics Completes $6.5M Series A Financing
01/07/2020: Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa
01/07/2020: Aegle Therapeutics welcomes Elona Baum, Lonnie Moulder and David Schimel to its Board of Directors
08/09/2019: Aegle Wins Debra’s Partners in Progress Award, Plans to Soon Open Clinical Trial in DEB Patients
05/20/2019: Aegle Therapeutics Corp. Receives IND Clearance from FDA for Its MSC-Derived Extracellular Vesicle Therapy for Dystrophic Epidermolysis Bullosa
05/15/2018: Aegle Therapeutics Corporation today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle expects to initiate a Phase 1/2a clinical trial of AGLE-102 for the treatment of severe burn patients in late 2018
04/10/2018: Aegle Therapeutics researchers publish Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts in Biochimie, April 10, 2108
12/19/2017: Aegle announces the appointment of Dr. Robert Ryan, CEO of Innova Therapeutics, to its board of directors
Publications
The effect of mesenchymal stem cells improves the healing of burn wounds: a phase 1 dose-escalation clinical trial. Scars Burn Heal. 2022 Jun 28;8:20595131211070783.
Immunological mechanisms underlying progression of chronic wounds in recessive dystrophic epidermolysis bullosa.. Exp Dermatol. 2021 Dec;30(12):1724-1733..
Proteomic analysis of bone marrow-derived mesenchymal stem cell extracellular vesicles from healthy donors: implications for proliferation, angiogenesis, Wnt signaling and the basement membrane. Stem Cell Res Ther 12, 328 (2021).
Exosomes: a clinical compendium. Academic Press. ISBN: 9780128160534.
Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts. Biochimie. 2018 Dec;155:50-58.
Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro. Stem Cells Dev. 2015 Jul 15;24(14):1635-47.